Brain AI diagnosis market set to nearly triple by 2030

The market for brain artificial intelligence-assisted diagnosis tools is projected to grow from $2.19 billion in 2025 to $6.84 billion by 2030, driven by rising neurological disease rates, faster imaging workflows and broader adoption of AI in clinical care. North America held the largest share in 2025 as hospitals and providers leaned further into AI-enabled diagnostics.

Why it matters: - Brain AI-assisted diagnosis tools are becoming more important as providers face more neurological disease cases and need faster, more accurate reads of scans and clinical data. - The market’s projected jump from $2.19 billion in 2025 to $6.84 billion by 2030 points to growing demand for AI in routine neurology workflows. - The shift could affect earlier detection of strokes, brain tumors and neurodegenerative disease, along with treatment planning and clinician workload.

What happened: - The Business Research Company released its Brain Artificial Intelligence (AI)-Assisted Diagnosis Solution Global Market Report 2026 – Market Size, And Forecast 2026-2035. - The report says the market will rise from $2.19 billion in 2025 to $2.76 billion in 2026. - The report projects a 25.8% compound annual growth rate for the 2025-2026 period. - The company expects the market to reach $6.84 billion by 2030 at a 25.5% CAGR. - The report frames brain AI-assisted diagnosis software as a tool for analyzing brain imaging and clinical data to detect neurological disorders. - The report says the solutions support earlier and more accurate diagnosis of strokes, brain tumors and neurodegenerative diseases. - The report says the tools can reduce interpretation time and human error while improving treatment planning and patient outcomes.

The details: - The report ties recent market growth to more medical imaging procedures. - The report also cites a rising number of neurological disorder cases. - Greater reliance on radiology for diagnosis has helped drive adoption. - Early use of AI-based clinical tools has supported expansion. - Better imaging quality and resolution have also contributed. - Looking ahead, the report expects demand for timely and accurate neurological diagnoses to remain a major driver. - The report points to more investment in AI-enabled healthcare solutions. - Cloud-based medical platforms are expected to expand use cases. - Regulatory approvals for AI diagnostic technologies are expected to increase. - The report sees deeper integration of AI into clinical workflows. - Emerging trends include broader use of AI-driven brain imaging analytics. - Deep learning adoption in neurology is expected to increase. - Clinical decision support systems are expected to grow. - Cloud diagnostic services are expected to expand. - The report expects more focus on detecting disease at an early stage. - The report says North America held the largest market share in 2025. - It includes coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America's lead is linked to advanced healthcare infrastructure, higher AI investment and supportive regulation.

Between the lines: - The report suggests the market is moving from experimental AI use to broader clinical deployment. - Rising dementia and other neurological cases strengthen the case for decision-support software that can help clinicians sort through growing imaging volumes. - The emphasis on cloud platforms and clinical workflow integration points to a market where distribution and adoption may matter as much as model accuracy. - NHS data cited in the report showed 487,432 dementia patients diagnosed by June 30, 2024, up 3,155 from the previous month. - That case count underscores the scale of neurological demand that AI tools may try to address.

What's next: - The market is expected to keep expanding through 2030 as AI imaging analytics and cloud diagnostics become more common. - Wider regulatory acceptance could accelerate hospital adoption. - More providers are likely to test or expand AI-assisted tools for early detection and workflow support. - The report’s updated 2026 package adds TAM analysis, company scoring matrices, forecasting dashboards and trend graphics.

The bottom line: - Brain AI-assisted diagnosis is moving into a high-growth phase, with demand rising as healthcare systems look for faster and more precise neurological screening.